3. Azmitia, E. C.; Segal, M.: An autoradiographic analysis of the dif- 22.
ferential ascending projections of the dorsal and median raphe. J.
Comp. Neurol. 179:641–668; 1978.
4. Bendotti, C.; Servadio, A.; Forloni, G.; Angeretti, N.; Samanin,
R.: Increased tryptophan hydroxylase mRNA in raphe serotonergic neurons spared by 5,7-dihydroxytryptamine. Mol. Brain Res. 23.
8:343–348; 1990.
5. Briley, M.; Chopin, P.; Moret, C.: Effect of serotonergic lesion on
“anxious” behavior measured in the elevated plus-maze test in
the rat. Psychopharmacology (Berlin) 101:187–189; 1990. 24.
6. Carli, M.; Prontera, C.; Samanin, R.: Evidence that central
5-hydroxytryptaminergic neurons are involved in the anxiolytic
activity of buspirone. Br. J. Pharmacol. 96:829–836; 1989.
7. Carli, M.; Samanin, R.: Potential anxiolytic properties of 8-hydroxy- 25.
2-(di-n-propylamino)tetralin, a selective serotonin1A receptor
agonist. Psychopharmacology (Berlin) 94:84–91; 1988.
8. Critchley, M. A. E.; Njung'e, K.; Handley, S. L.: Actions and
some interactions of 5-HT-1A ligands in the elevated X-maze and 26.
effects of dorsal raphe lesions. Psychopharmacology (Berlin)
106:484–490; 1992.
9. Deakin, J. F.; Graeff, F. G.: Critique: 5-HT and mechanisms of
defence. J. Psychopharmacol. 5:305–315; 1991. 27.
10. File, S. E.; Hyde, J. R. G.; MacLeod, N. K.: 5,7-Dihydroxytryptamine lesions of dorsal and median raphe nuclei and performance in the social interaction test of anxiety and in a home-cage
aggression test. J. Affect. Disord. 1:115–122; 1979. 28.
11. Frankfurt, M.; Mendelson, S. D.; McKittrick, C. R.; McEwen, B. S.:
Alterations of serotonin receptor binding in the hypothalamus
following acute denervation. Brain Res. 60:349–352; 1993.
12. Graeff, F. G.; Guimaraes, F. S.; de Andrade, T. G. C. S.; Deakin, 29.
J. F. W.: Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav. 54:129–141; 1996.
13. Hogg, S.: A review of the validity and variability of the elevated
plus-maze as an animal model of anxiety. Pharmacol. Biochem. 30.
Behav. 54:21–30; 1996.
14. Kirby, L. G.; Kreiss, D. S.; Singh, A.; Lucki, I.: Effect of destruction of serotonin neurons on basal and fenfluramine-induced 31.
serotonin release in striatum. Synapse 20:99–105; 1995.
15. König, J. F. R.; Klippel, R. A.: A stereotactic atlas. Baltimore:
Williams & Wilkins; 1963.
16. Lopez-Rubalcava, C.; Fernandez-Guasti, A.: Noradrenaline- 32.
serotonin interactions in the anxiolytic effects of 5-HT-1A agonists. Behav. Pharmacol. 5:42–51; 1994.
17. Lorens, S. A.; Guldenberg, H. C.; Hole, K.; Kohler, C.; Srebro,
B.: Activity, avoidance learning and regional 5-hydroxytryptamine following intra-brain stem 5,7-dihydroxytryptamine and 33.
electrolytic midbrain raphe lesions in the rat. Brain Res. 108:97–
113; 1976.
18. Manrique, C.; Segu, L.; Héry, F.; Hery, M.; Faudon, M.; FrancoisBellan, A. M.: Increase of central 5-HT-1B binding sites follow- 34.
ing 5,7-dihydroxytryptamine axotomy in the adult rat. Brain Res.
623:345–348; 1993.
19. Marsden, C. A.; Beckett, S. R. G.; Wilson, W.; Bickerdike, M.;
Fink, H.; Rex, A.; Cadogan, A.-K.: Serotonin involvement in ani- 35.
mal models of anxiety and panic. In: Takade, A.; Curzon, G., eds.
Serotonin in the central nervous system and periphery. Amsterdam: Elsevier; 1995:135–143.
20. Patel, T. D.; Azmitia, E. C.; Zhou, F. C.: Increased 5-HT-1A 36.
receptor immunoreactivity in the rat hippocampus following 5,7- dihydroxytryptamine lesions in the cingulum bundle and fimbriafornix. Behav. Brain Res. 73:319–323; 1996. 37.
Paxinos, G.; Watson, C.: The brain stereotaxic coordinates. New
York: Academic Press; 1986.
